Search details
1.
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
N Engl J Med
; 386(16): 1519-1531, 2022 04 21.
Article
in English
| MEDLINE | ID: mdl-35443108
2.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
; 141(2): 156-167, 2023 01 12.
Article
in English
| MEDLINE | ID: mdl-35714312
3.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38423051
4.
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Cancer
; 2024 Jun 19.
Article
in English
| MEDLINE | ID: mdl-38896056
5.
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol
; 204(3): 877-886, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37952982
6.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10388): 1571-1583, 2023 05 13.
Article
in English
| MEDLINE | ID: mdl-37116523
7.
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Blood
; 140(17): 1845-1857, 2022 10 27.
Article
in English
| MEDLINE | ID: mdl-35917453
8.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood
; 140(15): 1674-1685, 2022 10 13.
Article
in English
| MEDLINE | ID: mdl-35960871
9.
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Blood
; 139(23): 3366-3375, 2022 06 09.
Article
in English
| MEDLINE | ID: mdl-35081255
10.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Haematologica
; 109(2): 543-552, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-37560813
11.
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Haematologica
; 109(1): 115-128, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-37199127
12.
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
Haematologica
; 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38634126
13.
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Ann Hematol
; 103(2): 451-461, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38110588
14.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
JAMA
; 331(21): 1814-1823, 2024 06 04.
Article
in English
| MEDLINE | ID: mdl-38722621
15.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med
; 383(26): 2526-2537, 2020 12 24.
Article
in English
| MEDLINE | ID: mdl-33369355
16.
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Blood
; 137(14): 1879-1894, 2021 04 08.
Article
in English
| MEDLINE | ID: mdl-33150388
17.
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
Haematologica
; 108(4): 969-980, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-36325893
18.
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Haematologica
; 108(8): 2059-2066, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-36815361
19.
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Haematologica
; 108(1): 34-41, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-35678031
20.
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Eur J Haematol
; 111(3): 485-490, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37381686